255 results about "Purine-Xanthine Oxidase" patented technology

(Aza)indolizine derivatives represented by Formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In Formula (I), 0 to 2 of X¹, X², X³ and X⁴ are a nitrogen atom and the others are CR¹; one of T¹ and T² represents cyano and the other represents a group represented by Formula (A), with the proviso that when T¹ is cyano, at least one of X¹ to X⁴ is a nitrogen atom; R¹ independently represents a hydrogen atom, a halogen atom, a hydroxy group, C_1-6 alkyl, C_1-6 alkoxy or the like; ring U represents a benzene ring or the like; m represents integral number from 0 to 2; R² independently represents a fluorine atom, a hydroxy group or the like.

The invention relates to application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout and further provides medicine or health-care food for treating hyperuricemia and gout. Celery seed extract serves as the active constituent, and an appropriate number of medical carriers or auxiliary constituents are added, so that a preparation is obtained. The medicine for health-care food is simple in preparation process, the celery seed extract can obviously lower serum uric acid of model mice suffering from hyperuricemia caused by oteracil potassium salt, lower the activity of xanthine oxidase to different degrees, achieve an obvious inhibition effect on arthritis of the mice, prevent and treat hyperuricemia or gout and be applied to preparation of the medicine or health-care food for resisting to hyperuricemia and gout.

The invention disclosed an aryl nitrile group thiazole derivative for inhibiting the activity of xanthine oxidase, a method for preparing the same and application thereof. In the aryl nitrile group thiazole, R1 is methyl, ethyl, propyl, isopropyl, isobutyl, methyl cyclopropane, methyl cyclobutane, isoamyl, methyl cyclopentane, methyl cyclohexane or aromatic ring methyl, R2 is methyl or trifluoromethyl, and R3 is formic acid, sodium formate, potassium formate, lithium formate, methyl formate, or ethyl formate. Simultaneously, the invention discloses a method for synthesizing the aryl nitrile group thiazole derivative by using inexpensive raw materials, which has the advantages of simple operation, high yield, easy purification of products, application to industrial production and the like, and can obtain an efficient compound with low toxicity through screening; besides, the effective compound is expected to be widely applied to inhibit the activity of the xanthine oxidase required on animals and humans, and to become a new generation of antigout drugs and hyperuricemia drugs with special effect.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.

The invention relates to a polypeptide with a function of reducing uric acid and an application of the polypeptide. The polypeptide with the function of reducing uric acid has an amino acid sequence as follows: Tyr-Glu-Gly. The polypeptide is synthesized with a solid-phase synthesis method by the use of a polypeptide synthesizer. In-vitro uric acid reduction activity detection is performed on the polypeptide with an HPLC method, and a result proves that the polypeptide has a good inhibition effect on xanthine oxidase and has excellent uric acid reduction activity. The polypeptide can be used as an adjuvant therapy drug for the gout disease or used in functional health-care food or medicines with the function of reducing uric acid.

1-Phenylpyrazole compounds of the formula (1): which is exemplified by 5-amino-1-(3-cyano-4-isobutoxyphenyl)pyrazole-4-carboxylic acid, an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have a xanthine oxidase inhibitory activity and are useful as therapeutic agents for diseases such as hyperuricacidemia and gout.

The present invention relates to a composition for inhibiting xanthine oxidase comprising an effective amount of the extracts from Acacia spp.

The invention discloses lactobacillus fermentum for preventing and treating hyperuricemia as well as a composition and application thereof, wherein the lactobacillus fermentum GF1800 for preventing and treating hyperuricemia has the preservation number of CCTCC NO:M 2021984. The lactobacillus fermentum GF1800 is high in biological activity and strong in acid production capacity, can effectively inhibit the activity of pathogenic microorganisms and xanthine oxidase, can tolerate gastric acid and cholate, has a remarkable degradation effect on nucleoside substances, uric acid, cholesterol, nitrite and the like, can efficiently inhibit intake of exogenous uric acid and increase of endogenous uric acid, can obviously reduce the blood uric acid level of hyperuricemia, and meanwhile, improves intestinal and kidney structural injury and inflammatory response. The invention further discloses a composition containing the lactobacillus fermentum GF1800 and a strain metabolite and postbiotics of the lactobacillus fermentum GF1800 and an application of the lactobacillus fermentum GF1800 and the postbiotics of the lactobacillus fermentum GF1800 to preparation of functional food or medicine for preventing and treating hyperuricemia or/and gout, degrading nucleoside, inhibiting xanthine oxidase, reducing cholesterol, degrading nitrite and inhibiting pathogenic bacteria.

The invention discloses application of a gallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The gallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine. The formula (I) is as shown in the specification.

The invention particularly relates to a xanthine oxidase inhibitory peptide. The amino acid sequence of the xanthine oxidase inhibitory peptide is Glu-Glu-Ala-Lys (EEAK). The IC50 value of the tetrapeptide EEAK on xanthine oxidase inhibitory activity is 173.00+/-0.06 [mu]M, the tetrapeptide EEAK has a continuous and stable inhibitory effect on xanthine oxidase, and the tetrapeptide EEAK has the outstanding advantages of safety, no toxic or side effect, easiness in absorption, industrialization and the like. The active tetrapeptide EEAK or the derivative thereof can be used for preparing gout treatment/prevention medicines or used as a functional food additive for long-term treatment and health care of gout patients, and has a wide application prospect and very important significance.

The invention discloses a kidney bean bioactive peptide. The kidney bean bioactive peptide is prepared by the following method: 1) extracting proteins from kidney beans by adopting an alkali extraction and acid precipitation method; 2) dissolving the extracted proteins with water, then adding protease for enzymolysis, performing heating for inactivation, then performing centrifuging, and taking supernatant; and 3) filtering the supernatant with an ultrafiltration membrane, and performing freeze-drying to obtain the bioactive peptide. The kidney bean bioactive peptide provided by the inventionhas an inhibition effect on xanthine oxidase, and the in-vitro inhibition rate can reach 50% at most, so that the kidney bean bioactive peptide can be used for preparing xanthine oxidase inhibitors for in-vitro or in-vivo use or can be used for preparing uric acid reducing drugs for treating diseases such as hyperuricemia and gout.

The invention discloses a deuterium-substituted 2-phenylthiazole compound and a pharmaceutical composition thereof, and specifically relates to a deuterium-substituted 2-phenylthiazole compound with a general formula represented by formula (I), and a pharmaceutically acceptable salt thereof. At least one of R<3>, R<4>, and R<5> are used for representing deuterium or a substituent group containing deuterium. The deuterium-substituted 2-phenylthiazole compound is capable of inhibiting activity of xanthine oxidase. The deuterium-substituted 2-phenylthiazole compound or the pharmaceutically acceptable salt of the deuterium-substituted 2-phenylthiazole compound can be used for preparation of medicines used for preventing or treating hyperuricemia, gout, diabetic nephropathy, inflammatory diseases, and nervous system diseases.

The invention relates to aryl benzofuran amidated derivatives and a pharmaceutical use and a preparation method thereof; the derivatives have the antioxidant activity, have xanthine oxidase inhibitory activity, and can be used in preparation of compositions, drugs and health care products for resisting oxidation and treating gout and hyperuricemia.

The invention discloses a traditional Chinese medicine composite with a function of inhibiting alpha-glucuroide and xanthine oxidase and a preparation method and applications thereof. The bulk pharmaceutical chemical of the traditional Chinese medicine composite comprises drynaria rhizome, and also can comprise tuber fleeceflower stem, wherein, the weight ratio of drynaria rhizome to tuber fleeceflower stem is (0.5-2): 1, the preferential weight ratio is 1:1. The traditional Chinese medicine composite is based on two enzyme inhibitors of alpha-glucuroide and xanthine oxidase, and has double functions of reducing postprandial plasma glucose and blood uric acid. The invention has rich resource and low price, is safe and non-toxic, and has consistent function with Glucobay and allopurinol, thus the invention can be used for treating the diseases of glucose tolerance defect, diabetes, obesity, hyperuricemia and gout and the like.

The invention discloses a medicine for curing podagra, which is prepared by the raw materials with the weight proportions as follows: 15-25 parts of giant knotweed rhizome, 8-15 parts of salvia miltiorrhiza, 6-12 parts of rheum officinale, 12-17 parts of cuttlebone, 12-17 parts of isatis root, 12-17 parts of greater bunet root, 10-14 parts of herba scutellariae barbatae and 6-15 parts of radix bupleuri. The medicine for curing podagra provided by the invention has obvious effects on anti-inflammation and abirritation, can obviously lower the blood uric acid content and the activity of xanthine oxidase in livers, also can protect kidney and improve the organism condition, has excellent therapeutic effect on podagra; the therapeutic effect is excellent, the adverse reaction is little, the toxic side effect is not obvious, and the medicine is obviously better than the anti-podagra medicines clinically used at present.

The invention relates to scutellaprostin compounds, methods for preparing the same and pharmaceutical uses of the same. Particularly, the invention relates to preparation methods and pharmaceutical uses of A cyclo-dioxane scutellaprostin compounds capable of inhibiting the activities of xanthine oxidase, protecting brain nerve cells from oxidative damages and preventing and treating senile dementia. The compounds have strong inhibition effect on the activities of the xanthine oxidase and are expected to be used to prepare drugs or pharmaceutical compositions for preventing and treating diseases such as gout caused by the xanthine oxidase. The compounds have strong anti-oxidative damage and protective effects on PC12 cells simulating brain nerve cells and are expected to be used to prepare drugs or pharmaceutical compositions for protecting brain nerves, preventing aging and preventing and treating senile dementia.